Based on the research data available through Pillser, Saccharomyces boulardii is primarily studied for gastrointestinal health outcomes rather than systemic inflammation.

Here's what the evidence shows:

Primary researched benefits:

• Reduced Diarrhea Rate — 2 studies, both showing beneficial effects
• Reduced Duration of Diarrhea — 1 study showing benefit
• Reduced Symptom Severity — 2 studies (1 beneficial, 1 neutral)
• Improved SIBO Eradication — 1 study showing benefit
• Increased Antibacterial Activity Against Pathogens — 1 study showing benefit

Regarding inflammation specifically:
Pillser's database does not contain dedicated studies on Saccharomyces boulardii for reducing inflammation as a primary outcome. Interestingly, one study in the database found that it increased Interleukin 8 (IL-8) levels, which is a pro-inflammatory cytokine involved in immune response — though this was noted as a beneficial effect, likely in the context of immune defense against pathogens.

In summary: Pillser's evidence does not currently support the use of Saccharomyces boulardii specifically for reducing inflammation in the body. Its strongest evidence base is for managing diarrhea, reducing duration and severity of gastrointestinal symptoms, and supporting the eradication of certain gut infections like SIBO. If you're looking to reduce inflammation, other supplements may be more directly supported by the research.

For more details, you can explore the full research profile on the Saccharomyces boulardii page at Pillser.